Immudicon

Immudicon is an early stage biotechnology company pursuing a novel vaccine intracellular delivery technology, MacroVax, to activate the immune system against cancer and potentially other disease indications. The platform is based on an immunoprotein linked to horseshoe crabs that functions in humans via complement-associated pathways in order to generate T cells specific to tumor cells. The primary research and development of the technology has been shown in vitro in both mouse and human cells lines, as well as in vivo to explicate T cell specificity to tumor antigens, cytokine activation profiles, and early-stage prophylactic trials.